Clinical trial
ProQuad® Intramuscular vs Subcutaneous
NCT00402831 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00402831 |
|---|---|
| Title | ProQuad® Intramuscular vs Subcutaneous |
| Official title | An Open, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of ProQuad® When Administered by Intramuscular (IM) Route or Subcutaneous (SC) Route to Healthy Children Aged 12 to 18 Months |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Measles, Mumps, Rubella, Varicella |
| Intervention type | Biological |
| Interventions | ProQuad® |
| Enrollment | 405 |
| Start date | Oct 6, 2006 |
| Primary completion | May 11, 2007 |
| Completion | May 11, 2007 |
| First posted | Nov 22, 2006 |
| Last update posted | Aug 13, 2018 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: